Psyence BioMed reinforces its vertically integrated pharmaceutical platform through its investment in PsyLabs, securing GMP manufacturing, compound supply, and long term commercial infrastructure.
Psyence BioMed Put Option exercised by PsyLabs initiates a $5 million share for share exchange, deepening strategic alignment and reinforcing long term access to pharmaceutical grade psychedelic supply as clinical programs advance.
Psyence BioMed Put Option exercised by PsyLabs initiates a $5 million share for share exchange, deepening strategic alignment and reinforcing long term access to pharmaceutical grade psychedelic supply as clinical programs advance.
Psyence BioMed Annual and Special Meeting results confirm shareholder approval of directors, auditors and potential share consolidation authority of up to 250 to 1.
The Put Option Agreement positions Psyence BioMed for potential significant future equity participation in one of the world's most advanced psychedelic pharmaceutical grade manufacturers, thereby securing predictable and reliable supply of pharmaceutical grade psychedelics, as the pathway to commercialization unfolds.
Psyence announced that it has entered into a settlement agreement to resolve a direct shareholder claim made by KAOS Capital Ltd ("KAOS").
Psyence Biomed today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) of the Company's issued and outstanding common shares.
Psyence Biomed today announced that it adjourned its annual and special meeting of shareholders (the “Meeting”) until February 12, 2026.
Psyence Biomed today announced that it has decided to postpone the previously announced effective date of its reverse stock split of its issued and outstanding shares of common stock.
Psyence Biomedical Ltd. announced that its Board of Directors (the “Board”) has approved its 2026 Financial Strategy and Capital Management Framework, which includes the authorization of a share repurchase program that the management may undertake in value generation conditions.
